The english version of the website of the School of Medicine is under development

Δημοσίευση

Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: Study. A more efficient combination.

TitleAerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: Study. A more efficient combination.
Publication TypeJournal Article
Year of Publication2018
AuthorsSapalidis, K., Zarogoulidis P., Pavlidis E., Laskou S., Katsaounis A., Koulouris C., Giannakidis D., Mantalovas S., Huang H., Bai C., Wen Y., Wang L., Sardeli C., Amaniti A., Karapantzos I., Karapantzou C., Hohenforst-Schmidt W., Konstantinou F., Kesisoglou I., & Benhanseen N.
JournalJ Cancer
Volume9
Issue11
Pagination1973-1977
Date Published2018
ISSN1837-9664
Abstract

Lung cancer is the leading cause of cancer death after prostate cancer for males and breast cancer for females. There are novel therapies in the past five years such as; tyrosine kinase inhibitors and most recently in the last two years immunotherapy. Immunotherapy is currently being investigated if it can be administered alone or in combination. Previously we have investigated whether immunotherapy compounds can be produced as aerosols, and in the current study we investigated the safety and efficiency independently of the programmed death-ligand 1. The aerosol administration of both cisplatin and nivolumab is possible. The combination of the two drugs has a synergistic effect and therefore should be considered an option. Time of administration for immunotherapy is also very important.

DOI10.7150/jca.24782
Alternate JournalJ Cancer
PubMed ID29896282
PubMed Central IDPMC5995940

Contact

Secretariat of the School of Medicine
 

Connect

Schoole of Medicince presence in social networks
Follow Us or Connect with us.